Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.84 USD | -0.78% |
|
-1.46% | +40.49% |
Jun. 30 | Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index | CI |
Jun. 30 | Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Defensive Index | CI |
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | 7.29 | 5.33 | 3.36 | 5.62 | 4.67 | |||
Return on Total Capital | 7.38 | 5.41 | 3.39 | 5.68 | 4.73 | |||
Return On Equity % | 21.22 | 12.32 | 2.33 | 17.34 | 13.03 | |||
Return on Common Equity | 9.07 | 11.7 | 0.75 | 18.67 | 12.75 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 89.12 | 80.22 | 59.58 | 76.19 | 67.64 | |||
SG&A Margin | 8.56 | 7.99 | 10.16 | 10.61 | 10.46 | |||
EBITDA Margin % | 79.32 | 63.5 | 41.51 | 63.61 | - | |||
EBITA Margin % | 79.32 | 63.5 | 41.51 | 63.37 | 57.1 | |||
EBIT Margin % | 78.24 | 62.49 | 41.25 | 63.37 | 57.1 | |||
Income From Continuing Operations Margin % | 80.19 | 54.21 | 10.28 | 72.2 | 58.79 | |||
Net Income Margin % | 45.94 | 27.07 | 1.91 | 48.2 | 37.95 | |||
Net Avail. For Common Margin % | 23.33 | 27.07 | 1.91 | 48.2 | 37.95 | |||
Normalized Net Income Margin | 11.41 | 7.56 | 16.39 | 12.68 | 10.53 | |||
Levered Free Cash Flow Margin | -51.21 | -67.52 | -61.87 | -52.89 | -77.69 | |||
Unlevered Free Cash Flow Margin | -46.81 | -63.87 | -57.58 | -48.8 | -72.33 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.15 | 0.14 | 0.13 | 0.14 | 0.13 | |||
Receivables Turnover (Average Receivables) | 3.8 | 3.5 | 3.17 | 3.13 | 2.88 | |||
Short Term Liquidity | ||||||||
Current Ratio | 8.76 | 16.81 | 2.19 | 7.9 | 1.44 | |||
Quick Ratio | 8.73 | 16.77 | 2.11 | 7.87 | 1.43 | |||
Operating Cash Flow to Current Liabilities | 6.61 | 11.78 | 1.84 | 18.51 | 2.21 | |||
Days Sales Outstanding (Average Receivables) | 96.37 | 104.35 | 115.07 | 116.5 | 127.05 | |||
Average Days Payable Outstanding | 17.4 | 6.61 | 2.73 | 7.51 | 7.13 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 58.78 | 69.24 | 74.71 | 60.84 | 73.6 | |||
Total Debt / Total Capital | 37.02 | 40.91 | 42.76 | 37.83 | 42.4 | |||
LT Debt/Equity | 58.78 | 69.24 | 64.24 | 60.84 | 63.96 | |||
Long-Term Debt / Total Capital | 37.02 | 40.91 | 36.77 | 37.83 | 36.84 | |||
Total Liabilities / Total Assets | 38.23 | 41.49 | 43.35 | 38.44 | 43.24 | |||
EBIT / Interest Expense | 9.89 | 8.61 | 4.91 | 7.97 | 5.73 | |||
EBITDA / Interest Expense | 10.02 | 8.75 | 4.94 | 8 | - | |||
(EBITDA - Capex) / Interest Expense | 10.02 | 8.75 | 4.94 | 8 | - | |||
Total Debt / EBITDA | 3.46 | 4.88 | 7.66 | 4.1 | - | |||
Net Debt / EBITDA | 2.23 | 3.38 | 5.79 | 3.77 | - | |||
Total Debt / (EBITDA - Capex) | 3.46 | 4.88 | 7.66 | 4.1 | - | |||
Net Debt / (EBITDA - Capex) | 2.23 | 3.38 | 5.79 | 3.77 | - | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 16.98 | 7.87 | -2.28 | 5.24 | -3.86 | |||
Gross Profit, 1 Yr. Growth % | -33.25 | -2.9 | -27.42 | 34.58 | -14.65 | |||
EBITDA, 1 Yr. Growth % | -36.4 | -13.65 | -36.12 | 61.31 | - | |||
EBITA, 1 Yr. Growth % | -36.4 | -13.65 | -36.12 | 60.69 | -13.38 | |||
EBIT, 1 Yr. Growth % | -36.7 | -13.84 | -35.49 | 61.68 | -13.38 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | -30.85 | -27.07 | -81.46 | 638.96 | -21.72 | |||
Net Income, 1 Yr. Growth % | -58.48 | -36.44 | -93.09 | 2.55K | -24.31 | |||
Normalized Net Income, 1 Yr. Growth % | -81.77 | -24.87 | 111.72 | -18.56 | -20.15 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | - | 12.97 | -93.44 | 2.49K | -24.54 | |||
Accounts Receivable, 1 Yr. Growth % | 27.48 | 8.99 | 6.63 | 6.48 | 6.56 | |||
Total Assets, 1 Yr. Growth % | 28.68 | 9.34 | -4.01 | -2.57 | 11.24 | |||
Tangible Book Value, 1 Yr. Growth % | -20.87 | 20.48 | -2.73 | 16.23 | 6.38 | |||
Common Equity, 1 Yr. Growth % | -21.08 | 19.88 | -2.57 | 15.96 | 6.44 | |||
Cash From Operations, 1 Yr. Growth % | 22.04 | -0.84 | 6.27 | 39.36 | -7.32 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 218.6 | 42.24 | -10.49 | -10.03 | 41.2 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 606.31 | 47.16 | -11.94 | -10.81 | 42.5 | |||
Dividend Per Share, 1 Yr. Growth % | - | 126.67 | 11.76 | 5.26 | 5 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 8.74 | 12.34 | 2.67 | 1.41 | 0.59 | |||
Gross Profit, 2 Yr. CAGR % | 1.05 | -19.49 | -16.05 | -1.17 | 7.18 | |||
EBITDA, 2 Yr. CAGR % | 9.75 | -25.89 | -25.73 | 1.51 | - | |||
EBITA, 2 Yr. CAGR % | 9.75 | -25.89 | -25.73 | 1.31 | 17.98 | |||
EBIT, 2 Yr. CAGR % | 10.32 | -26.15 | -25.45 | 2.12 | 18.34 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 5.89 | -28.99 | -63.23 | 17.03 | 140.51 | |||
Net Income, 2 Yr. CAGR % | -15.87 | -48.63 | -79.04 | 35.32 | 347.82 | |||
Normalized Net Income, 2 Yr. CAGR % | -33.96 | -63.89 | 26.12 | 31.31 | -19.36 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -81.25 | - | -72.77 | 30.4 | 342.15 | |||
Accounts Receivable, 2 Yr. CAGR % | 10.77 | 17.87 | 7.8 | 6.55 | 5.54 | |||
Total Assets, 2 Yr. CAGR % | 18.7 | 18.61 | 2.45 | -3.29 | 4.11 | |||
Tangible Book Value, 2 Yr. CAGR % | 4.19 | -2.36 | 8.26 | 6.33 | 11.2 | |||
Common Equity, 2 Yr. CAGR % | 3.62 | -2.73 | 8.07 | 6.29 | 11.1 | |||
Cash From Operations, 2 Yr. CAGR % | 12.13 | 10 | 2.65 | 21.69 | 13.64 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 112.88 | 12.84 | -10.26 | 12.71 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 222.4 | 13.85 | -11.38 | 12.74 | |||
Dividend Per Share, 2 Yr. CAGR % | - | - | 59.16 | 8.47 | 5.13 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 9.92 | 8.45 | 7.24 | 3.52 | -0.38 | |||
Gross Profit, 3 Yr. CAGR % | 16.47 | -0.28 | -22.23 | -1.75 | -5.88 | |||
EBITDA, 3 Yr. CAGR % | 20.05 | 1.32 | -29.47 | -3.82 | - | |||
EBITA, 3 Yr. CAGR % | 20.05 | 1.32 | -29.47 | -3.94 | -3.84 | |||
EBIT, 3 Yr. CAGR % | 20.9 | 1.59 | -29.4 | -3.5 | -3.33 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 8.21 | -6.49 | -54.62 | -0.04 | 2.35 | |||
Net Income, 3 Yr. CAGR % | -6.94 | -23.38 | -73.68 | 5.19 | 11.5 | |||
Normalized Net Income, 3 Yr. CAGR % | -16.49 | -32.18 | -34.89 | 9.01 | 11.25 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | -65.89 | - | 24.31 | 8.67 | |||
Accounts Receivable, 3 Yr. CAGR % | - | 10.18 | 14 | 7.36 | 5.9 | |||
Total Assets, 3 Yr. CAGR % | - | 15.49 | 10.53 | 0.75 | 1.33 | |||
Tangible Book Value, 3 Yr. CAGR % | - | 9.36 | -2.48 | 10.85 | 6.35 | |||
Common Equity, 3 Yr. CAGR % | - | 8.78 | -2.68 | 10.64 | 6.34 | |||
Cash From Operations, 3 Yr. CAGR % | 12.78 | 7.63 | 8.74 | 13.66 | 11.13 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 59.5 | 4.64 | 4.38 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 109.21 | 4.95 | 3.82 | |||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | 38.67 | 7.3 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 6.96 | 5.58 | 4.52 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 2.17 | -0.64 | -11.58 | |||
EBITDA, 5 Yr. CAGR % | - | - | -0.93 | 1.39 | - | |||
EBITA, 5 Yr. CAGR % | - | - | -0.93 | 1.32 | -13.36 | |||
EBIT, 5 Yr. CAGR % | - | - | -0.36 | 1.81 | -13.2 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | -29.73 | 2.29 | -11.57 | |||
Net Income, 5 Yr. CAGR % | - | - | -48.74 | -3.8 | -18.22 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | -2.49 | -11.66 | -29.07 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | -41.67 | - | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 8.71 | 10.54 | |||
Total Assets, 5 Yr. CAGR % | - | - | - | 7.58 | 7.92 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 8.14 | 2.77 | |||
Common Equity, 5 Yr. CAGR % | - | - | - | 7.78 | 2.61 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 8.62 | 13.05 | 10.68 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 38.82 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 63.37 |
- Stock Market
- Equities
- RPRX Stock
- Financials Royalty Pharma plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions